Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor monotherapy versus dual antiplatelet therapy after PCI in chronic coronary syndrome
IRCT20240701062299N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ticagrelor, aspirin and clopidogrel in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: stent thrombosis and bleeding. Started Jul 2024; status: completed.
02
Drugs
ticagreloraspirinclopidogrel
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20240701062299N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240701062299N1.